Thursday, April 26, 2018

12.40-12.50 Welcome Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres

Session I – Etiology of MDS

Chair: Pierre Fenaux

12.50-13.20 Therapy related MDS and other environmental factors in MDS Maria Theresa Voso (Rome)
13.20-13.25 Discussion

13.25-13.45 Genetic predisposition to MDS and acute leukemia Jude Fitzgibbon (London)
13.45-13.50 Discussion

13.50-14.10 Association between MDS and immunological disorders, and other clinical associations Olivier Fain (Paris)
14.10-14.15 Discussion

14.15-14.35 Clinical usefulness of somatic mutations in MDS/CMML in the context of the WHO 2016 classification David Steensma (Boston)
14.35-14.40 Discussion

Brief Oral Communication:

14.40-14.47 A landscape of germline mutations in inherited bone marrow failure (BMF) and MDS patients Marie Sébert (Paris)

14.47-15.00 Panel Discussion

15.00-15.30 Coffee break

Session II – Biology of MDS: Genetic abnormalities

Chair: Mikkael Sekeres

15.30-15.50 MDS methylation missteps and molecular correlates Maria (Ken) Figueroa (Miami)
15.50-15.55 Discussion

15.55-16.15 Walk this way: The multiple acquired clonal steps to MDS Jaroslaw P. Maciejewski (Cleveland)
16.15-16.20 Discussion

16.20-16.40 Telomere maintenance and MDS: cause or consequence? Tim Brümmendorf (Aachen)
16.40-16.45 Discussion
16.45-17.05 The many faces of TP53 Torsten Haferlach (Munich)
17.05-17.10 Discussion

Brief Oral Communications:

17.10-17.17 Involvement of co-occurring STAG2 and RAS signaling mutations in the progression from MDS to sAML assessed by whole-exome and targeted-deep sequencing Marta Martin-Izquierdo (Salamanca)
17.17-17.24 Differential expression of the homologous recombination DNA repair genes in early and advanced stages of myelodysplastic syndrome Jan Valka (Prague)

17.25-17.40 Panel Discussion

17.40-17.55 ESH-AAMDS Scholarships Award Ceremony Chair: Mikkael Sekeres

Free evening

Friday, April 27, 2018

8.00-09.00 Simultaneous Meet the Expert Sessions
• Clinical usefulness of somatic mutations in MDS/CMML David Steensma (Boston)
• Flow in MDS: How, when and why? Arjan Van de Loosdrecht (Amsterdam)
• Technical aspects: Analysis of somatic mutations, of SNP etc. Jaroslaw P. Maciejewski (Cleveland)

9.00-10.00 SATELLITE SYMPOSIUM
EMERGING MOLECULAR INSIGHTS IN MDS: IMPLICATIONS FOR DRUG DEVELOPMENT AND NOVEL TREATMENT STRATEGIES
Speakers: Lionel Ades (Paris), Michael Heuser (Hannover), David Roth (Cambridge, USA), David Steensma (Boston)

This educational symposium is organized and funded by Syros

10.00-10.30 Coffee break

Session III – Biology of MDS: stem cells and the microenvironment

Chair: Uwe Platzbecker

10.30-10.50 The niche in MDS: Inflammation driving evolution Marc H.G.P. Raaijmakers (Rotterdam)
10.50-10.55 Discussion

10.55-11.15 Bone biology and the osteo-hematopoietic niche Lorenz C. Hofbauer (Dresden)
11.15-11.20 Discussion

11.20-11.40 Hematopoietic stem cells in MDS: The real targets? Ulrich Steidl (New York)
11.40-11.45 Discussion
Mesenchymal stem cells in MDS: The better targets?
Hind Medyoun (Frankfurt)

Dysregulation of the immune system in MDS
Shahram Kordasti (London)

Brief Oral Communication:

Role of transcription factors implicated in late megakaryopoiesis in patients with higher-risk myelodysplastic syndrome or low-blast count acute myeloid leukemia, receiving azacitidine as bridge to hematopoietic stem cell transplantation
Carmelo Gurnari (Rome)

Panel Discussion

Session IV – Diagnostic workup and prognostic factors in MDS
Chair: Arjan Van de Loosdrecht

Morphology (including WHO 2016 classification), cytogenetics and flow cytometry
Ari Giagounidis (Düsseldorf)

Discussion

Prognostic factors in MDS
Luca Malcovati (Pavia)

Discussion

New biological predictive factors for specific treatments in MDS
Raphaël Itzykson (Paris)

Discussion

Quality of life in MDS
Fabio Efficace (Rome)

15.40-16.10 DEBATE: Are cytogenetics still useful in MDS?
Yes: Claudia Haferlach (Munich)
No: Austin Kulasekaraj (London)

General treatment algorithm in MDS
Pierre Fenaux (Paris)

Discussion

Brief Oral Communication:

A novel complete blood count-based score allows for early distinction of myelodysplastic syndrome in patients with cytopenia of unknown origin
Marion Eveillard (Nantes)

Coffee break

Session V – Specific subtypes of MDS, based on morphology and molecular biology
Chair: Eva Hellström-Lindberg

Cause and effect of splicesomes and ring sideroblasts
Luca Malcovati (Pavia)

Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.40-18.00</td>
<td>CMML and other MDS/MPNs</td>
<td>Eric Solary (Villejuif)</td>
</tr>
<tr>
<td>18.00-18.05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18.05-18.25</td>
<td>What’s the deal with del(5q)?</td>
<td>Ari Giagounidis (Düsseldorf)</td>
</tr>
<tr>
<td>18.25-18.30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18.30-18.50</td>
<td>Childhood MDS: Not just little adults</td>
<td>Christian Flotho (Freiburg)</td>
</tr>
<tr>
<td>18.50-18.55</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Brief Oral Communication:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.55-19.02</td>
<td>RAS pathway hyperactivation is associated with inferior survival in patients with chronic myelomonocytic leukemia</td>
<td>Klaus Geissler (Vienna)</td>
</tr>
<tr>
<td>19.02-19.17</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>19.20</td>
<td>Tutored poster walks (Authors to be in front of their poster)</td>
<td>Biology: Raphaël Itzykson and Ulrich Steidl</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical: Arjan Van de Loosdrecht and David Steensma</td>
</tr>
</tbody>
</table>

Get-together finger food dinner reception

---

**Saturday, April 28, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Simultaneous Meet the Expert Sessions</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30-8.30</td>
<td>• Treatment of higher risk MDS</td>
<td>Mikkael Sekeres (Cleveland)</td>
</tr>
<tr>
<td></td>
<td>• Treatment of lower risk MDS</td>
<td>Lionel Adès (Paris)</td>
</tr>
<tr>
<td></td>
<td>• Treatment of CMML</td>
<td>Raphaël Itzykson (Paris)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Session VI – Treatment of MDS**

Chair: Valeria Santini

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.45-9.05</td>
<td>Growth factors: When and how?</td>
<td>Eva Hellström-Lindberg (Stockholm)</td>
</tr>
<tr>
<td>9.05-9.10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9.10-9.30</td>
<td>HMAs: When and how?</td>
<td>Valeria Santini (Florence)</td>
</tr>
<tr>
<td>9.30-9.35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>9.35-9.55</td>
<td>Allo Tx: When and how?</td>
<td>Uwe Platzbecker (Dresden)</td>
</tr>
<tr>
<td>9.55-10.00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Brief Oral Communications:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-10.07</td>
<td>Anti-human CD117 antibody mediates depletion of myelodysplastic syndrome hematopoietic stem cells and facilitate establishment of normal hematopoiesis in transplantation</td>
<td>Wendy W. Pang (Stanford)</td>
</tr>
<tr>
<td>10.07-10.14</td>
<td>MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia</td>
<td>Michaela Dostalova Merkerova (Prague)</td>
</tr>
</tbody>
</table>
Transfusions in patients with MDS—Results of 2017 UK national comparative audit
Marina Karakantza (Bournemouth)

10.21-10.35 Panel Discussion

10.35-11.05 Coffee break

Management of HMA failure
Lionel Ades (Paris)

11.05-11.25 Discussion

11.30-11.50 Novel strategies to treat cytopenia in LR-MDS
Uwe Platzbecker (Dresden)

11.50-11.55 Discussion

11.55-12.15 Strategies to improve HMA based therapy
Mikkael Sekeres (Cleveland)

12.15-12.20 Discussion

Brief Oral Communication:

A high pre-treatment bone marrow CD34+/CD38- cell burden in patients with MDS is a prognostic factor for disease progression after allogeneic stem cell transplantation
Barbara Madlen Jentzsch (Leipzig)

12.20-12.27 Panel Discussion

12.45-12.50 Conclusion

Meeting closure